Phosphodiesterase Inhibitors

Neglected diseases, such as African Sleeping Sickness, have a big impact on human health and cause a major economic burden on developing countries. The parasites that cause sleeping sickness depend on enzymes called 'phosphodiesterases'. Distortion of the function of these enzymes is lethal for the parasites, which makes the enzyme a potential drug target.

Developing drugs for these diseases is commercially not feasible for a single company but the social need is very high. With support and advocacy of TI Pharma, an international partnership was started that brings together all relevant expertise to develop a possible treatment.

Partners

Drugs for Neglected Diseases initiative
University Bern
Nycomed
VU University Amsterdam
Mercachem
IOTA Pharmaceuticals
Royal Tropical Institute

For more information, please contact info@tipharma.com 
or call +31 71 332 2030

     

    “TI Pharma's program managers are experts in the content, enabling them to keep parties focused on the goals that were agreed upon at the outset.”

    Jan Raaijmakers
    Past VP External Scientific Collaborations GSK Europe
    Chair TI Pharma Board of Directors

    Share this page: